It was hardly a rebound, but Aveo Pharmaceuticals Inc. gained some ground Wednesday, a day after its stock plummeted 31.3 percent as the Food and Drug Administration said it may require another clinical trial of the Cambridge company’s drug for advanced renal cell carcinoma, tivozanib. The FDA had been scheduled to decide by July 28 whether to approve the drug but raised questions about whether it improves survival rates more than a drug that’s already available.
Aveo stock rebounds a bit after big plunge
You have reached the limit of 10 free articles in a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than 25¢ a week